Chemoinformaics analysis of (E)-3-Hydroxyfarnesa-1,6,10-trien-9-yl isobutyrate
| Molecular Weight | 308.462 | nRot | 9 |
| Heavy Atom Molecular Weight | 276.206 | nRig | 4 |
| Exact Molecular Weight | 308.235 | nRing | 0 |
| Solubility: LogS | -3.932 | nHRing | 0 |
| Solubility: LogP | 4.16 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 54 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 22 | No. of Aromatic Carbocycles | 0 |
| nHetero | 3 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 32 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 19 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 3 | No. of Arom Bond | 0 |
| nHA | 3 | APOL | 55.4734 |
| nHD | 1 | BPOL | 34.7066 |
| QED | 0.501 |
| Synth | 4.07 |
| Natural Product Likeliness | 2.724 |
| NR-PPAR-gamma | 0.029 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.932 |
| Pgp-sub | 0.005 |
| HIA | 0.012 |
| CACO-2 | -4.484 |
| MDCK | 0.0000242 |
| BBB | 0.791 |
| PPB | 0.939693 |
| VDSS | 1.554 |
| FU | 0.0972184 |
| CYP1A2-inh | 0.067 |
| CYP1A2-sub | 0.161 |
| CYP2c19-inh | 0.565 |
| CYP2c19-sub | 0.86 |
| CYP2c9-inh | 0.25 |
| CYP2c9-sub | 0.716 |
| CYP2d6-inh | 0.054 |
| CYP2d6-sub | 0.086 |
| CYP3a4-inh | 0.826 |
| CYP3a4-sub | 0.437 |
| CL | 7.163 |
| T12 | 0.216 |
| hERG | 0.005 |
| Ames | 0.017 |
| ROA | 0.007 |
| SkinSen | 0.465 |
| Carcinogencity | 0.099 |
| EI | 0.068 |
| Respiratory | 0.017 |
| NR-Aromatase | 0.013 |
| Antiviral | Yes |
| Prediction | 0.568534 |